Kinase targeting in Luminal A breast cancer: CLK1.

Breast cancer can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2).  Disease recurrence following disease remission (relapse), resistance to endocrine therapy or otherwise inadequate long-term control of disease are challenges that limit effectiveness of existing drugs that treat luminal A and luminal B receptor disease.  Here we utilized whole transcriptome technologies (5, 6) to measure total transcription in the primary tumors of humans with luminal A and luminal B breast cancer.  We describe one member of a group of kinases up-regulated and differentially expressed in human luminal A breast cancer, CLK1, as a catalytically available enzyme and candidate therapeutic target for the adjunctive medical treatment of luminal A breast cancer.